Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Study of Ketamine as an Antidepressant


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01441505

Organisation Name: The University of New South Wales

Overal Status: Unknown status

Start Date: September 2011

Last Update: February 22, 2013

Lead Sponsor: The University of New South Wales

Brief Summary: Recently, interest has emerged in the use of ketamine as an antidepressant. Recent placebo-controlled clinical trials administering a single dose and an open label trial giving repeated doses shown that ketamine is markedly superior to placebo at reducing depression, including in treatment-resistant patients, and that its antidepressant effects have a very rapid onset.

This clinical study consists of two phases. In Phase I, participants who satisfy inclusion criteria will receive ketamine at variable doses (0.1mg/kg-0.5mg/kg) or a placebo (saline, or 0.01mg/kg midazolam) once a week over up to 6 weeks. If participants qualify for Phase II, they will receive repeated sessions of ketamine at variable doses over three weeks. During both phases, mood, psychiatric, and neuropsychological outcomes will be measured.

Conditions:
  • Major Depressive Episode


Total execution time in seconds: 0.18750500679016